Full Title
MMRC Horizon One: A Phase II Randomized Adaptive Platform Trial Evaluating Novel Therapies in Relapsed or Refractory Multiple Myeloma (WIRB)Purpose
Researchers are examining different therapies to treat multiple myeloma that came back or keeps growing after treatment. In this study, they are assessing different dosing schedules of teclistamab, a drug already used to treat multiple myeloma.
Teclistamab is given as an injection under the skin. The goal is to see if lower doses or stopping treatment will have the same benefit with fewer side effects.
If you join this study, you will be randomly assigned to get one of these treatments:
- Teclistamab every 4 weeks.
- Teclistamab every 12 weeks.
- You will stop teclistamab and be observed. If your cancer shows signs of growing, doctors will resume giving you teclistamab.
Who Can Join
To join this study, there are a few conditions. You must:
- Have multiple myeloma that came back or keeps growing after up to 4 prior regimens of treatment.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Saad Usmani’s office at 646-608-4165.
Protocol
24-404
Phase
Phase II (phase 2)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT06171685